Exploring Shootin1’s oncogenic role within FGFR2 gene fusions

Our findings establish <i>FGFR2</i>::<i>SHTN1</i> as a potent oncogenic driver in various cancers, particularly in cholangiocarcinoma, highlighting a unique mechanism of constitutive activation mediated by Shootin1's CCD-II domain. This study represents the first molecular characterization of the <i>FGFR2</i>::<i>SHTN1</i> fusion, advances understanding of <i>FGFR2</i> fusion biology, and identifies a particular target for future diagnostic and therapeutic strategies in relevant malignancies.